Back to funds
View filing
GREAT POINT PARTNERS LLC
hedge fundUpdated 27 days agoManaged by Great Point Partners Llc • Latest filing Q2 2026
Portfolio value
$529.1M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
51.6%
Weight of largest holdings
Annualized return
1.2%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $509.3M |
| Q2 2023 | $510.8M |
| Q3 2023 | $549M |
| Q4 2023 | $586.7M |
| Q1 2024 | $641.6M |
| Q2 2024 | $522M |
| Q3 2024 | $339.8M |
| Q4 2024 | $212.2M |
| Q1 2025 | $188.8M |
| Q2 2025 | $153.8M |
| Q3 2025 | $242.5M |
| Q4 2025 | $308.4M |
| Q1 2026 | $435.1M |
| Q2 2026 | $529.1M |
Top holdings
42 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | A AAVXF ABIVAX SA | $53.3M | 400.0K | 10.07% | — |
| 2 | V VOR VOR BIOPHARMA INC | $31.3M | 1.70M | 5.91% | Trimmed(-2.9%) |
| 3 | A AAVXF ABIVAX SA | $27.2M | 204.3K | 5.15% | — |
| 4 | H HWM IMMUNITYBIO INC | $26.3M | 3.00M | 4.97% | Unchanged |
| 5 | V VERA VERA THERAPEUTICS INC | $25.8M | 600.8K | 4.87% | Added(+201.4%) |
| 6 | Z ZURA ZURA BIO LTD | $24.9M | 4.22M | 4.70% | Unchanged |
| 7 | A ALMS ALUMIS INC | $24.1M | 856.1K | 4.55% | Unchanged |
| 8 | S SLGL SOL-GEL TECHNOLOGIES LTD | $20.3M | 274.4K | 3.84% | Unchanged |
| 9 | R RARE ULTRAGENYX PHARMACEUTICAL IN | $20M | 600.0K | 3.79% | — |
| 10 | D DFTX DEFINIUM THERAPEUTICS INC | $20M | 425.0K | 3.78% | — |
| 11 | A ANNX ANNEXON INC | $20M | 3.50M | 3.78% | Added(+40.0%) |
| 12 | O ORKA ORUKA THERAPEUTICS INC | $17.4M | 183.3K | 3.30% | Unchanged |
| 13 | M MLTX MOONLAKE IMMUNOTHERAPEUTICS | $16.7M | 855.8K | 3.15% | Added(+71.2%) |
| 14 | S SGMT SAGIMET BIOSCIENCES INC | $15.7M | 2.03M | 2.97% | — |
| 15 | C CTNM CONTINEUM THERAPEUTICS INC | $15.1M | 921.5K | 2.85% | Added(+15.2%) |
| 16 | ? N/A IMMIX BIOPHARMA INC | $13.2M | 1.28M | 2.49% | Added(+265.0%) |
| 17 | ? N/A CLIMB BIO INC | $13M | 1.00M | 2.46% | Trimmed(-25.0%) |
| 18 | A AMLX AMYLYX PHARMACEUTICALS INC | $12.6M | 700.0K | 2.38% | Trimmed(-60.0%) |
| 19 | N NKTR NEKTAR THERAPEUTICS | $12.2M | 175.0K | 2.31% | Trimmed(-44.7%) |
| 20 | N NGNE NEUROGENE INC | $11.1M | 352.2K | 2.09% | Trimmed(-29.6%) |